

Our Ref: DH/SW/SL

7th July 1982

Dr. G. Stephenson,
British Technology Group,
Kingsgate House,
66-74 Victoria Street,
London,
SW1E 6SL.

Dear Gerard,

Factor VIII:C Purification Patent Application

My thanks to Stephen Crespi and yourself for your most helpful guidance this morning.

As I explained we are now much happier about the patentability of the above application, due to the specificity of the clone 132 claims.

I would like to deposit the myeloma cell line and file the patent in the names of Tuddenham, Rothbart, and Goodhall, having first had B.T.G.'s assurance that they would have no objection to the inventors assigning the rights to Speywood. I will ask Jeremy Collier to let you have sight of the draft as soon as it is available. Hopefully, you will then be able to give me a written O.K. to go ahead.

Producing 'Pure Factor FVIII:C', for clinical use, is not going to be a commercially viable proposition and therefore will probably never generate any monies for the inventors, but, we feel it will be a useful factor in the patent protection built around biosynthetic factor VIII production. Naturally if you feel that the B.T.G. requires a stake in the possible revenues from this patent, we would be only too pleased to discuss this. However, our main concern is to patent a.s.a.p.

I look forward to hearing from you.

Kind Regards.

Yours sincerely,

David Heath